Abstract 415P
Background
RET fusion is one of the rare driver genes in lung cancer and thyroid carcinoma and and RET-directed therapies have shown promising results in this unique population. The aim of this study was to investigate the efficacy of cabozantinib in patients with advanced RET fusion NSCLC.
Methods
A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2019. To determine the frequency of the RET fusions in NSCLC and other tumors, we analyzed data from 3046 clinical NSCLC cases, each of which had results from next-generation sequencing (NGS)-based 381 genes panel assay, analogous to the index patient.
Results
Of this entire cohort, 61 (2.00%) patients were identified with a RET fusion, including KIF5B-RET (40), CCDC6-RET (16), NCOA4-RET (1), ANK3-RET (1), ERC1-RET (1), RYFY2-RET (1) and CSGALNACT2-RET (1). 8 cases coexist with EGFR mutations, were all used EGFR-TKIs treatment. For treatments, 14.75% (9/61) patients chose cabozantinib, other patients chose chemotherapy or chemoradiotherapy, and case examples of advanced RET fusion driven NSCLC patients responding to cabozantinib were actively being sought thru our database.
Conclusions
Patients with advanced RET fusion NSCLC showed a relatively good outcome of cabozantinib with relatively large side effects, which strengthen the need for effective RET-targeted drugs in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chun-wei Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session